1. Global challenges in the development and delivery of paediatric antiretrovirals
2. EMA(n.d.‐a).Orphan designation: overview.https://www.ema.europa.eu/en/human‐regulatory/overview/orphan‐designation‐overview#rare‐diseases‐at‐a‐glance‐section(accessed February 2021).
3. EMA(n.d.‐b).Applying for orphan designation.https://www.ema.europa.eu/en/human‐regulatory/research‐development/orphan‐designation/applying‐orphan‐designation(accessed February 2021).
4. FDA(1998a).Orphan drugs. The CDER Handbook. Revised 16 March 1998: 75.https://drive.google.com/file/d/0B0xuPGwlJiiVNU0wZE4wZlRSREU/edit(accessed January 2021).
5. FDA(1998b).CDER Pediatric Initiatives. The CDER Handbook. Revised 16 March 1998: 81‐82.https://drive.google.com/file/d/0B0xuPGwlJiiVNU0wZE4wZlRSREU/edit(accessed January 2021).